Literature DB >> 3007597

Effects of prednisolone on acute viral myocarditis in mice.

N Tomioka, C Kishimoto, A Matsumori, C Kawai.   

Abstract

The effect of prednisolone on viral myocarditis was studied in BALB/c mice with encephalomyocarditis virus myocarditis. Prednisolone was injected intramuscularly, 10 mg/kg once a day, on days 4 to 13 (experiment 1) and on days 8 to 17 (experiment 2). The control mice in each experiment received injections of distilled water. In experiment 1, myocardial virus titers were maximal but neutralizing antibodies were rarely present on day 4, and viral titers were still elevated and antibody titers were high on day 8. The survival rate of the prednisolone group was significantly lower (p less than 0.05) than that of the control group on days 21, 22 and 23. On day 10, the antibody titers of the prednisolone group were significantly lower (p less than 0.01) than those of the control group, and viral titers of the prednisolone group remained significantly elevated (p less than 0.01), whereas viruses were rarely isolated in the control group. In experiment 2, the survival rate and antibody titers were not significantly different in the prednisolone and control groups. In both experiments, no viruses were isolated on day 14. The present study suggests that corticosteroids given in the early stage aggravate the course of acute viral myocarditis, and that they may not have detrimental effects if given when neutralizing antibody titer levels are high, although they are not expected to have a beneficial effect.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3007597     DOI: 10.1016/s0735-1097(86)80349-7

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  23 in total

1.  Immune suppressive treatment in paediatric myocarditis: still awaiting the evidence.

Authors:  M Burch
Journal:  Heart       Date:  2004-10       Impact factor: 5.994

Review 2.  Immunomodulating therapy in experimental myocarditis.

Authors:  A Matsumori; C Kawai
Journal:  Springer Semin Immunopathol       Date:  1989

Review 3.  Recognition and optimum management of myocarditis.

Authors:  A L Caforio; W J McKenna
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

4.  Coxsackievirus B-3 myocarditis. T-cell autoimmunity to heart antigens is resistant to cyclosporin-A treatment.

Authors:  M Estrin; C Smith; S Huber
Journal:  Am J Pathol       Date:  1986-11       Impact factor: 4.307

5.  Verapamil ameliorates the clinical and pathological course of murine myocarditis.

Authors:  R Dong; P Liu; L Wee; J Butany; M J Sole
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

6.  Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. Suppression of natural killer cell activity and tumor necrosis factor-alpha production.

Authors:  S Matsui; A Matsumori; Y Matoba; A Uchida; S Sasayama
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

7.  The effects of lobenzarit disodium, a novel immunomodulator, upon murine coxsackievirus B3 myocarditis.

Authors:  H Takada; C Kishimoto; Y Kuroki; I Matsushita; Y Hiraoka; M Kurokawa; H Ochiai; S Sasayama
Journal:  Heart Vessels       Date:  1993       Impact factor: 2.037

8.  Enhanced expression of superoxide dismutase messenger RNA in viral myocarditis. An SH-dependent reduction of its expression and myocardial injury.

Authors:  H Suzuki; A Matsumori; Y Matoba; B S Kyu; A Tanaka; J Fujita; S Sasayama
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

9.  Cytomegalovirus myocarditis following liver transplantation.

Authors:  W A Stack; H E Mulcahy; L Fenelon; J E Hegarty
Journal:  Postgrad Med J       Date:  1994-09       Impact factor: 2.401

10.  Immunohistochemical characterization of infiltrating mononuclear cells in the rat heart with experimental autoimmune giant cell myocarditis.

Authors:  M Kodama; S Zhang; H Hanawa; A Shibata
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.